CJC-1295 No DAC 5mg + IPA 5mg

CJC-1295 NO DAC is the standard form of a synthetic growth hormone-releasing hormone analogue that does not include Drug Affinity Complex (DAC) modification.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively targets ghrelin receptors, specifically the GHS-R1a receptor, with high binding specificity.

When combined, CJC-1295 No DAC and Ipamorelin provide a dual-pathway research model for studying growth hormone regulation through both GHRH and ghrelin signalling systems.  CJC-1295 NO DAC activates GHRH receptors in the anterior pituitary, increasing cyclic adenosine monophosphate (cAMP) via adenylyl cyclase activation, while Ipamorelin stimulates ghrelin receptors through a separate G-protein coupled pathway that also elevates cAMP through an alternative mechanism. This parallel activation enables investigation of potential synergistic interactions between the two systems.

This combination is used in research to explore how complementary signalling pathways may influence growth hormone secretion patterns, including both immediate and sustained release dynamics.

Research applications include:

• Growth hormone physiology
• Receptor pharmacology
• Interaction between dual secretagogue pathways.

The 5 mg + 5 mg formulation is used to evaluate balanced activity between both components.